Skip to main content

Table 3 QALYs in preterm neonates and infants with RSV adjusted for level of care and disutilities caused by recurrent wheezing in infancy

From: Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

Clinical parameter

QALYs & disutilities

Ref

RSV without hospitalization.

0.95 (95% CI: 0.76–1.00)

[18, 19]

Hospitalization in the general ward.

0.88 (95% CI: 0.70–1.00)

[15]

Hospitalization in the ICU without acute complications.

0.73 (95% CI: 0.58–0.87)

[15]

Hospitalization in the ICU with acute complications.

0.51 (95% CI: 0.40–0.60)

[15]

Disability due to recurrent wheezing (similar to asthma).

0.087

[16]